Simplify Logo

Full-Time

Director – Patient Services

Posted on 7/24/2024

Axsome Therapeutics Inc

Axsome Therapeutics Inc

501-1,000 employees

Develops therapies for CNS disorders

Hardware
Biotechnology

Compensation Overview

$190k - $215kAnnually

+ Bonus + Equity

Expert

New York, NY, USA

Category
Project Management
Business & Strategy
Requirements
  • Bachelor’s/Undergraduate Degree
  • 9+ years in a pharmaceutical commercial function
  • 5+ years of specific focus on co-pay, PAP, HUB, and similar patient service programs
  • Ability to work on site Monday, Tuesday & Thursday
Responsibilities
  • Lead the design, development, and implementation of patient service programs and initiatives
  • Oversee the management of third-party vendors providing services on behalf of Axsome
  • Conduct periodic reviews of business rules for each program
  • Evaluate the effectiveness of patient service programs
  • Identify opportunities to improve patient access
  • Work with internal and external partners to ensure integration and consistency of business strategies
  • Provide education and guidance to Leadership on patient service trends
  • Identify strategic initiatives through active monitoring of industry trends
  • Consistently execute multiple projects in an on time and on budget manner
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Growth & Insights
Headcount

6 month growth

92%

1 year growth

92%

2 year growth

92%
Simplify Jobs

Simplify's Take

What believers are saying

  • The launch of Auvelity and the promising results of AXS-12 in Phase 3 trials indicate strong potential for revenue growth and market impact.
  • Axsome's strategic expansion of its sales force to support Auvelity's launch demonstrates its commitment to commercial success.
  • The appointment of experienced leaders like Dr. Sue Mahony to the board enhances Axsome's strategic direction and governance.

What critics are saying

  • The biopharmaceutical sector's inherent risks, including regulatory hurdles and clinical trial failures, could impact Axsome's progress.
  • High competition in the CNS disorder treatment market may challenge Axsome's ability to capture significant market share.

What makes Axsome Therapeutics Inc unique

  • Axsome Therapeutics focuses on CNS disorders with a strong emphasis on unmet medical needs, setting it apart from broader biopharmaceutical companies.
  • The FDA Breakthrough Therapy Designation for AXS-05 highlights its innovative approach and potential for rapid market entry.
  • Axsome's diversified pipeline, including treatments for MDD, TRD, Alzheimer's agitation, and narcolepsy, showcases its comprehensive strategy in CNS therapeutics.
INACTIVE